文献速递肝病

美国瘦型非酒精性脂肪性肝病患者肝硬化及共病患病率较低

Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-07-03

基于TARGET-NASH研究3386例非酒精性脂肪性肝病患者,按体重指数分类发现12.8%为瘦型,其中亚洲人占48.7%。瘦型患者肝硬化、心血管疾病、糖尿病、高血压、血脂异常比例均低于非瘦型;调整年龄、性别和中心类型后,瘦型亚洲人非酒精性脂肪性肝病相关肝硬化比值比(OR)为0.47(95%CI 0.29-0.77),约为瘦型非亚洲人的一半。

要点

  • 美国非酒精性脂肪性肝病人群中超过10%为瘦型,亚洲人占瘦型近一半。
  • 瘦型患者肝硬化、心血管疾病及代谢异常比例均低于非瘦型患者。
  • 瘦型亚洲人非酒精性脂肪性肝病相关肝硬化OR为0.47(95%CI 0.29-0.77)。

核心结论

  • 在美国非酒精性脂肪性肝病人群中,超过10%为瘦型,亚洲人占瘦型近一半;瘦型患者肝硬化、心血管疾病和代谢异常比例低于非瘦型。
  • 亚洲参与者在所有体重指数分类中肝硬化、心血管疾病和代谢异常比例均显著低于非亚洲参与者。

研究设计与样本

  • TARGET-NASH研究,2016年8月至2019年3月共纳入3386例非酒精性脂肪性肝病患者,按体重指数分类分析肝硬化、心血管疾病和代谢异常患病率,并按年龄和种族估计比值比,调整性别和中心类型。

主要发现

  • 研究参与者中12.8%为瘦型,27.1%为超重,26.5%为1级肥胖,33.7%为2级或3级肥胖。
  • 瘦型参与者中亚洲人占48.7%,随体重指数分类升高比例下降(P < .0001)。
  • 瘦型参与者肝硬化比例为22.6%,非瘦型为40.2%。
  • 瘦型参与者心血管疾病史比例为9.0%,非瘦型为14.8%;糖尿病比例为32.6% vs 53.5%,高血压比例为47.8% vs 67.4%,血脂异常比例为54.0% vs 64.1%。
  • 调整年龄、性别和中心类型及站点后,瘦型亚洲人非酒精性脂肪性肝病相关肝硬化OR为0.47(95%CI 0.29-0.77),约为瘦型非亚洲人的一半。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Nonalcoholic fatty liver disease (NAFLD) is typically associated with obesity. Little is known about the prevalence of cirrhosis in patients with NAFLD and a normal body mass index (BMI). METHODS: We determined prevalence of cirrhosis, cardiovascular disease (CVD), and metabolic abnormalities among participants in all BMI categories in the TARGET-NASH study. A total of 3386 patients with NAFLD were enrolled from August 2016 through March 2019. The odds ratios of cirrhosis, CVD, and metabolic abnormalities were estimated by age and race, adjusting for sex and center type. RESULTS: Based on standard BMI cutoff values, 12.8% of study subjects were lean, 27.1% were overweight, 26.5% had class 1 obesity, and 33.7% had class 2 or 3 obesity. Asians accounted for 48.7% of lean participants, and proportions decreased as BMI categories increased (P < .0001). Lower proportions of lean participants had cirrhosis (22.6% vs 40.2% of non-lean participants), CVD history (9.0% vs 14.8% of nonlean participants), diabetes (32.6% vs 53.5% of non-lean participants), hypertension (47.8% vs 67.4% of non-lean participants), or dyslipidemia (54.0% vs 64.1% of non-lean participants). Asian participants had a lower prevalence of cirrhosis, history of CVD, cardiovascular events, and diabetes compared with non-Asians, independent of BMI category. After we adjusted for age, sex, and center type and site, the odds of NAFLD-associated cirrhosis in Asians who were lean was almost half the odds of NAFLD-associated cirrhosis in non-Asians who were lean (odds ratio, 0.47; 95% CI, 0.29-0.77). CONCLUSIONS: More than 10% participants in a cohort of persons with NAFLD in the United States are lean; Asians account for almost half of the lean persons with NAFLD. Lean participants had a lower prevalence of cirrhosis, CVD, and metabolic abnormalities than non-lean persons with NAFLD. Asian participants had a significantly lower prevalence of cirrhosis, CVD, and metabolic abnormalities than non-Asians in all BMI categories. ClinicalTrials.gov, Number: NCT02815891.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Weinberg EM, Trinh HN, Firpi RJ, et al. Lean Americans With Nonalcoholic Fatty Liver Disease Have Lower Rates of Cirrhosis and Comorbid Diseases. Clin Gastroenterol Hepatol. 2020. PMID: 32629123. doi:10.1016/j.cgh.2020.06.066

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。